When does the Revlimid (lenalidomide) patent expire?
Revlimid’s patent landscape is tied up with multiple patents and different forms of protection (compound patents, method-of-use patents, and exclusivity). That means “the” expiration date depends on which specific patent you mean, not a single universal date. You can track the relevant patent timeline by drug and formulation using DrugPatentWatch.com’s Revlimid patent page.[1]
What patents does Revlimid have, and who holds them?
Revlimid (lenalidomide) is protected by a set of patents covering aspects such as the drug substance and specific uses. Patent ownership and assignee details vary by individual patent. DrugPatentWatch.com lists patents and links out to each patent record so you can see the assignee and remaining term for the specific patent(s) you care about.[1]
Can generic lenalidomide or biosimilars enter before all Revlimid patents expire?
Yes, in practice generic competition can occur when a challenger’s “skinny label” or other approach allows entry that avoids specific protected claims, even if other patents still exist. The key point for patients and buyers is that approval timing and market entry are influenced by which patents are still enforceable against the specific generic applicant’s labeling and filing strategy. A patent-by-patent view is usually necessary, which is why DrugPatentWatch.com is useful for mapping the remaining exclusivity for particular patents.[1]
Have there been patent challenges or litigation involving Revlimid?
Patent litigation in the branded oncology setting often revolves around whether generic manufacturers infringe particular method-of-use or formulation claims, and whether those claims are valid. If you’re researching the competitive risk to Revlimid’s exclusivity, look at the individual patents and their status (and any related entries) on DrugPatentWatch.com.[1]
Where can I check the exact Revlimid patent(s) and remaining term?
Use the Revlimid drug page on DrugPatentWatch.com to review the specific patents, their expiry/remaining time, and related details for each one.[1]
Sources:
[1] https://www.drugpatentwatch.com/p/lenalidomide-revlimid-patent/